Judah Frommer
Stock Analyst at Morgan Stanley
(3.92)
# 636
Out of 4,996 analysts
182
Total ratings
60.15%
Success rate
6.9%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $71 → $101 | $82.84 | +21.92% | 3 | Sep 12, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Overweight | $18 | $8.77 | +105.25% | 1 | Aug 21, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $22.39 | +16.12% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $26.14 | +64.50% | 2 | May 9, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $9.65 | +148.70% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $33.78 | -34.87% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $8.39 | -28.49% | 2 | Jan 13, 2025 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $79.69 | +33.02% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $11.71 | +198.89% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $2.09 | +522.01% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.49 | +20.48% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $2.47 | +1,519.43% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.42 | +815.49% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $42.95 | -30.15% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $24.14 | -4.72% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $58.99 | -15.24% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $18.36 | +667.97% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $5.27 | +70.78% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $28.50 | -22.81% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.54 | +26.35% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $8.84 | -9.50% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $32.68 | +40.76% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.65 | +164.15% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $54.31 | +1.27% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $137.03 | -66.43% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $104.30 | -53.02% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $915.95 | -59.60% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $76.60 | -59.53% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $81.94 | -7.25% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $102.12 | +78.22% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $95.06 | +12.56% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $132.40 | -28.25% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.56 | +2.51% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $154.76 | -25.05% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $93.10 | -59.18% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $109.88 | -79.98% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $65.46 | -46.53% | 9 | Apr 29, 2020 |
ABIVAX Société Anonyme
Sep 12, 2025
Maintains: Overweight
Price Target: $71 → $101
Current: $82.84
Upside: +21.92%
Trevi Therapeutics
Aug 21, 2025
Initiates: Overweight
Price Target: $18
Current: $8.77
Upside: +105.25%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $22.39
Upside: +16.12%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $26.14
Upside: +64.50%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $9.65
Upside: +148.70%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $33.78
Upside: -34.87%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $8.39
Upside: -28.49%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $79.69
Upside: +33.02%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $11.71
Upside: +198.89%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.09
Upside: +522.01%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.49
Upside: +20.48%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $2.47
Upside: +1,519.43%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.42
Upside: +815.49%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $42.95
Upside: -30.15%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $24.14
Upside: -4.72%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $58.99
Upside: -15.24%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $18.36
Upside: +667.97%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $5.27
Upside: +70.78%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $28.50
Upside: -22.81%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.54
Upside: +26.35%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $8.84
Upside: -9.50%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $32.68
Upside: +40.76%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.65
Upside: +164.15%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $54.31
Upside: +1.27%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $137.03
Upside: -66.43%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $104.30
Upside: -53.02%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $915.95
Upside: -59.60%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $76.60
Upside: -59.53%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $81.94
Upside: -7.25%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $102.12
Upside: +78.22%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $95.06
Upside: +12.56%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $132.40
Upside: -28.25%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.56
Upside: +2.51%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $154.76
Upside: -25.05%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $93.10
Upside: -59.18%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $109.88
Upside: -79.98%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $65.46
Upside: -46.53%